Clinical Trials Browser

Phase 2 × Not yet recruiting × osimertinib × Clear all

NCT07622186 2026-06-03

A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07603791 2026-05-22

Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK202 for Injection in Combination With Drugs in NSCLC Participants.

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07256509 2025-12-05

A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07177092 2025-09-16

SURGAN-TKI

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07038460 2025-06-26

NEO-LISI

Phase 2 Not yet recruiting

Resectable Non-small Cell Lung Cancer

NCT06918782 2025-04-09

Real-world Experience With Combination Chemotherapy and Osimertinib in Poor Prognostic Group of Metastatic EGFR-mutated Lung Adenocarcinoma

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06752408 2024-12-30

ANOTHER

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06692491 2024-11-18

SPRING

Phase 2 Not yet recruiting

Rare Tumour

NCT06530719 2024-07-31

A Study to Evaluate the Efficacy of Osimertinib in Patients With EGFR-sensitive Mutated Non-small Cell Lung Cancer Progression After Receiving Adjuvant Targeted Therapy Following Radical Surgery

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06452433 2024-06-11

Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer.

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06436144 2024-05-30

Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLC

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06319950 2024-03-20

High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases

Phase 2 Not yet recruiting

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT06142617 2023-11-21

A Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point Mutation.

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06018688 2023-09-21

Osimertinib Combined With Aspirin Neoadjuvant Therapy for Resectable EGFR Mutated NSCLC Patients.

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung